Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise
Marshall A. Mazepa
, Jay S. Raval
, Mark E. Brecher
, Yara A. Park
Medicine - Hematology, Oncology, Transplant
Research output
:
Contribution to journal
›
Article
›
peer-review
15
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of acquired Thrombotic Thrombocytopenic Purpura in the U.S. remains heterogeneous: Current and future points of clinical equipoise'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acquired Thrombotic Thrombocytopenic Purpura
100%
Clinical Equipoise
100%
Therapeutic Plasma Exchange
75%
Replacement Fluid
50%
Rituximab
25%
Medical Therapy
25%
Telephone
25%
Plasma Volume
25%
Platelet Count
25%
Plasma Exchange
25%
Apheresis
25%
Patient Volume
25%
Therapy Practice
25%
ADAMTS13
25%
Medicine and Dentistry
Plasma Exchange
100%
Thrombotic Thrombocytopenic Purpura
100%
Clinical Equipoise
100%
Combination Therapy
25%
Platelet
25%
Rituximab
25%
Apheresis
25%
Von Willebrand Factor Cleaving Proteinase
25%
Nursing and Health Professions
Thrombotic Thrombocytopenic Purpura
100%
Plasma Exchange
100%
Patient Volume
25%
Platelet Count
25%
Plasma Volume
25%
Combination Therapy
25%
Apheresis
25%
Von Willebrand Factor Cleaving Proteinase
25%
Rituximab
25%